FDA Approves First Biosimilar Insulin Product
- July 30, 2021
The Food and Drug Administration (FDA) approved July 28 Mylan Pharmaceuticals Inc.’s Semglee (insulin glargine-yfgn) as a biosimilar to reference product Lantus (insulin glargine), a long-acting insulin analog.
ARTICLE TAGS
You must be logged in to access this content.